Abstracts tagged "Social support and systemic lupus erythematosus (SLE)"

Abstract Number: 1243 • 2017 ACR/ARHP Annual Meeting
Clarifying Patient-Determined Barriers in Living with Systemic Lupus Erythematosus Treatment: A Qualitative Ethnographic Approach
Jerik Leung¹, Deepali Sen² and Alfred Kim³, ¹Internal Medicine/Rheumatology, Washington University School of Medicine, Saint Louis, MO, ²Division of Rheumatology, Washington University School of Medicine, St. Louis, MO, ³IM/Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: The patient-specific experience of living with SLE is underreported. While there are data addressing factors influencing the quality of life of patients with SLE,…
Abstract Number: 2515 • 2013 ACR/ARHP Annual Meeting
Social Capital: A Novel Platform For Understanding Social Determinants Of Health In Systemic Lupus Erythematosus
Susan Kim¹, Carol Mancuso², Wei-Ti Huang³ and Doruk Erkan⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Medicine, Hospital for Special Surgery, NY, NY, ³Biostatistics, Hospital for Special Surgery, New York, NY, ⁴Rheumatology Dept, Hospital for Special Surgery, New York, NY
Background/Purpose: Social capital is the degree of connectedness, and the extent and quality of social relations, networks, and interactions in a given population. The objective…
Abstract Number: 1887 • 2012 ACR/ARHP Annual Meeting
Facebook Support Groups in Systemic Lupus Erythematosus: Content Analysis
Evelyne Vinet¹, William Shihao Lao², Christian A. Pineau³, Ann E. Clarke⁴ and Sasha Bernatsky⁵, ¹McGill University Health Center, Montreal, QC, Canada, ²Medicine, McGill University, Montreal, QC, Canada, ³Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁴Clinical Epidemiology, MUHC, Montreal, QC, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Ctre, Montreal, QC, Canada
Background/Purpose: Facebook is the most important social network site, with over 600 million registered users worldwide. Many disease-specific groups exist on Facebook, offering a convenient…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].